Briahna Joy Gray and Robby Soave react to climate activists confronting Sen. Joe Manchin (D-W.Va.) #joemanchin #climate Photo Credit: Climate DefianceAbout R...
How DARE you curse at this honorable grifting destroyer of the planet, his coalness Lord Manchin!
This made me laugh. At 0:21 Manchin gets up pretending he’s a badass and he’s going to fight. As if he ever would.
No knowledgeable person would fight a senator. In fact - it’s a very smart move to back away. The US legal system would fuck over the “attacker” and claim even the teensiest, tiniest touch was an “assault”. And Manchin would sue them for damages in civil court too. The “attacker” would badly lose both legal cases.
That touch would give the person a jail sentence of many months if not longer. Manchin would also fuck them out of a lot of money. Judges in both cases would act like the “assailant” punched 100 cops in the face one after another. Guilty even before trial.
-–
Ninja edit
His daughter is also a massive piece of shit.
She's the reason a EpiPen costs hundreds of dollars. She got a $31 golden parachute for fucking people over.
In 2016, Mylan’s pricing of the EpiPen, used to treat anaphylaxis (severe allergic reactions), was severely criticized. Mylan had secured the rights to the nearly 50-year-old EpiPen as part of the Merck KGaA deal in 2007. At that time annual sales were around $200 million.
Bresch launched an advertising campaign to increase awareness of “EpiPen” as a treatment for anaphylaxis; the company also successfully lobbied the FDA to broaden the label to include risk of anaphylaxis and in parallel, successfully lobbied Congress to generate legislation making EpiPens available in schools and other public places. The company hired the same lobbyists that Medtronic had used for its defibrillator legislation.
From 2007 to 2016, Mylan increased the price of EpiPens by 461 percent, from about $100 for a package of two pens to about $600. By the first half of 2015, Mylan had an 85% market share of such devices in the U.S., and in that year sales reached around $1.5 billion and accounted for 40% of Mylan’s profit.
The price increase was met with widespread criticism of Bresch and Mylan. Bresch explained at the 2016 Forbes Healthcare Summit that Mylan’s price increases were justified by the many improvements she claimed the company had made to the product.
Amid this backlash, Bresch led Mylan to introduce a generic version of the device which sells for half the price of the brand-name device. The generic version in 2016 remained more expensive than the original brand version of EpiPen prior to Mylan’s purchase of the rights, even when accounting for inflation.
In July 2019, Bresch announced that she would retire in 2020 after Mylan merged with Upjohn. The merger was completed in November 2020 and Bresch stepped down. The new company was named Viatris. According to the Pittsburgh Business Journal, when she left Mylan, she was the second most highly paid executive in the area of Pittsburgh, and received a “golden parachute” estimated at $30.8 million.
In 2021, a case was ongoing to determine whether Mylan had attempted to monopolize the EpiPen market, with both Mylan N.V. and Bresch being sued on racketeering claims and anti-trust claims. The lawsuit, which consolidated several consumer cases, was moved to federal court in Kansas City in 2017. In February 2020, the lawsuit moved ahead as a nationwide class action.
On June 24, 2021, a federal judge tossed the racketeering claims and some of the antitrust claims, also dropping RICO claims against Bresch. The case went on trial on September 7, 2021. On September 7, 2021, Ryan Grim of The Intercept reported that during an ongoing racketeering case involving Mylan and Bresch, “newly released court documents show [Bresch] discussing a deal with Pfizer to eliminate a chief competitor to EpiPen, clearing the way for major price hikes.”
The 2010 and 2011 email discussions, unsealed by the judge, showed Bresch’s assistant discussing divesting from Adrenaclick after the closure of the Pfizer/King deal. They “also show Bresch approving a scheme to force customers, captured by the company’s monopoly, to purchase two EpiPens at once, regardless of medical need.”
The worst part is one of his security detail motioned Manchin to stand back, and then that security person shoved the protestor.
The same rules apply. That human thumb can assault the person protesting with complete immunity and if that protestor laid a finger on that CHUD the book would be thrown at him. Disgusting
The PG version of what I want to say is that I hope there’s a hell so the thumb can roast there for all eternity.
complete immunity
It really is a great example of how fucked up things are. I am merely mentioning this in a theoretical context - if somebody milkshaked Manchin - it might go to court as a biological weapon attack. “The senator is lactose intolerant, your honor…”
How DARE you curse at this honorable grifting destroyer of the planet, his coalness Lord Manchin!
This made me laugh. At 0:21 Manchin gets up pretending he’s a badass and he’s going to fight. As if he ever would.
No knowledgeable person would fight a senator. In fact - it’s a very smart move to back away. The US legal system would fuck over the “attacker” and claim even the teensiest, tiniest touch was an “assault”. And Manchin would sue them for damages in civil court too. The “attacker” would badly lose both legal cases.
That touch would give the person a jail sentence of many months if not longer. Manchin would also fuck them out of a lot of money. Judges in both cases would act like the “assailant” punched 100 cops in the face one after another. Guilty even before trial.
-–
Ninja edit
His daughter is also a massive piece of shit.
She's the reason a EpiPen costs hundreds of dollars. She got a $31 golden parachute for fucking people over.
Heather Bresch
EpiPen pricing and retirement
In 2016, Mylan’s pricing of the EpiPen, used to treat anaphylaxis (severe allergic reactions), was severely criticized. Mylan had secured the rights to the nearly 50-year-old EpiPen as part of the Merck KGaA deal in 2007. At that time annual sales were around $200 million.
Bresch launched an advertising campaign to increase awareness of “EpiPen” as a treatment for anaphylaxis; the company also successfully lobbied the FDA to broaden the label to include risk of anaphylaxis and in parallel, successfully lobbied Congress to generate legislation making EpiPens available in schools and other public places. The company hired the same lobbyists that Medtronic had used for its defibrillator legislation.
From 2007 to 2016, Mylan increased the price of EpiPens by 461 percent, from about $100 for a package of two pens to about $600. By the first half of 2015, Mylan had an 85% market share of such devices in the U.S., and in that year sales reached around $1.5 billion and accounted for 40% of Mylan’s profit.
The price increase was met with widespread criticism of Bresch and Mylan. Bresch explained at the 2016 Forbes Healthcare Summit that Mylan’s price increases were justified by the many improvements she claimed the company had made to the product.
Amid this backlash, Bresch led Mylan to introduce a generic version of the device which sells for half the price of the brand-name device. The generic version in 2016 remained more expensive than the original brand version of EpiPen prior to Mylan’s purchase of the rights, even when accounting for inflation.
In July 2019, Bresch announced that she would retire in 2020 after Mylan merged with Upjohn. The merger was completed in November 2020 and Bresch stepped down. The new company was named Viatris. According to the Pittsburgh Business Journal, when she left Mylan, she was the second most highly paid executive in the area of Pittsburgh, and received a “golden parachute” estimated at $30.8 million.
In 2021, a case was ongoing to determine whether Mylan had attempted to monopolize the EpiPen market, with both Mylan N.V. and Bresch being sued on racketeering claims and anti-trust claims. The lawsuit, which consolidated several consumer cases, was moved to federal court in Kansas City in 2017. In February 2020, the lawsuit moved ahead as a nationwide class action.
On June 24, 2021, a federal judge tossed the racketeering claims and some of the antitrust claims, also dropping RICO claims against Bresch. The case went on trial on September 7, 2021. On September 7, 2021, Ryan Grim of The Intercept reported that during an ongoing racketeering case involving Mylan and Bresch, “newly released court documents show [Bresch] discussing a deal with Pfizer to eliminate a chief competitor to EpiPen, clearing the way for major price hikes.”
The 2010 and 2011 email discussions, unsealed by the judge, showed Bresch’s assistant discussing divesting from Adrenaclick after the closure of the Pfizer/King deal. They “also show Bresch approving a scheme to force customers, captured by the company’s monopoly, to purchase two EpiPens at once, regardless of medical need.”
The worst part is one of his security detail motioned Manchin to stand back, and then that security person shoved the protestor.
The same rules apply. That human thumb can assault the person protesting with complete immunity and if that protestor laid a finger on that CHUD the book would be thrown at him. Disgusting
The PG version of what I want to say is that I hope there’s a hell so the thumb can roast there for all eternity.
It really is a great example of how fucked up things are. I am merely mentioning this in a theoretical context - if somebody milkshaked Manchin - it might go to court as a biological weapon attack. “The senator is lactose intolerant, your honor…”
I am vibrating with the amount of
I feel